Neurology & Brain Disorders Clinical Trials Update: Week 45, 2026

Published November 6, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease

This Phase 2 trial is exploring a new treatment option for people with early Alzheimer's disease. The study tests a monoclonal antibody designed to target tau protein in the brain, which is linked to the progression of Alzheimer’s. If successful, this treatment could help slow down cognitive decline and provide a new approach for managing early stages of the disease.

China HEalthy Aging and Dementia Study (HEAD)

The HEAD study is a large community-based research project in China enrolling over 20,000 adults who have or are at risk for Alzheimer’s disease and related dementias. By collecting detailed clinical and biological information, the study aims to improve early diagnosis and help predict who may experience cognitive decline. This could lead to more personalized care and better support for patients before symptoms become severe.

Intranasal Dexmedetomidine-esketamine Combination and Postoperative Cognitive Recovery in Older Patients

This upcoming Phase 4 trial will test a combination of two medications given through the nose to improve cognitive recovery after surgery in older adults. Many older patients face problems like confusion or delayed thinking after non-heart-related surgeries, and this study hopes to reduce these issues. If effective, the treatment could enhance quality of life during the critical recovery period after surgery.

Biomarkers for Monitoring Dementia Progression

This completed study in Italy looked at new ways to detect and track Alzheimer’s disease using biomarkers and anti-inflammatory nanoparticles. The research focused on people with mild Alzheimer's and mild cognitive impairment, aiming to find early signs of disease progression. These findings could lead to better monitoring techniques and innovative treatments that slow down memory loss and brain changes.

Flutemetamol F 18 Injection Formulation Comparison

This Phase 2 trial in the United States is testing a new version of a brain imaging agent used to detect amyloid plaques, which are associated with Alzheimer's disease. The goal is to improve how well patients tolerate the injection and to ensure consistent production of the agent. Better imaging tools can help doctors diagnose Alzheimer’s more accurately and monitor disease progression.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.